CytomX Therapeutics, Inc.
For the period ended Jun 30, 2026. Filed Aug 6, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Jun 30, 2026 · Filed Aug 6, 2026
CTMX$1.980.0%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Statements of Cash Flows
(in thousands)
| Six Months Ended | ||
|---|---|---|
| June 30, | ||
| 2026 | 2025 | |
| Cash flows from operating activities: | ||
| Net income (loss) | $(38,914) | $23,371 |
| Adjustments to reconcile net income (loss) to net cash used in operating activities: | ||
| Amortization of intangible assets | 73 | 73 |
| Depreciation and amortization | 225 | 659 |
| Accretion of discounts on short-term investments | (2,154) | (851) |
| Stock-based compensation expense | 7,283 | 3,439 |
| Non-cash lease expense | 2,497 | 2,189 |
| Changes in operating assets and liabilities | ||
| Accounts receivable | (35,481) | 1,234 |
| Prepaid expenses and other assets | (3,746) | (1,076) |
| Accounts payable | 638 | (853) |
| Accrued liabilities and other long-term liabilities | (261) | (3,209) |
| Deferred revenue | 26,223 | (61,772) |
| Net cash used in operating activities | (43,617) | (36,796) |
| Cash flows from investing activities: | ||
| Purchases of property and equipment | — | (146) |
| Purchases of short-term investments | (311,824) | (128,618) |
| Maturities of short-term investments | 125,000 | 83,000 |
| Net cash used in investing activities | (186,824) | (45,764) |
| Cash flows from financing activities: | ||
| Proceeds from issuance of pre-funded warrants, net of issuance cost | 5,855 | — |
| Proceeds from issuance of common stock, net of issuance cost | 228,407 | 93,373 |
| Proceeds from employee stock purchase plan and exercise of stock options | 736 | 177 |
| Net cash provided by financing activities | 234,998 | 93,550 |
| Net increase in cash, cash equivalents and restricted cash | 4,557 | 10,990 |
| Cash, cash equivalents and restricted cash, beginning of period | 14,194 | 39,079 |
| Cash, cash equivalents and restricted cash, end of period | $18,751 | $50,069 |
| Supplemental disclosures of noncash financing activities: | ||
| Right-of-use assets obtained in exchange for lease obligations | 4,138 | — |
| Common stock issuance costs included in accrued liabilities | 40 | — |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.